Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 75

1.

Comparison of Longitudinal CA125 Algorithms as a First-Line Screen for Ovarian Cancer in the General Population.

Blyuss O, Burnell M, Ryan A, Gentry-Maharaj A, Mariño IP, Kalsi J, Manchanda R, Timms JF, Parmar M, Skates SJ, Jacobs I, Zaikin A, Menon U.

Clin Cancer Res. 2018 Oct 1;24(19):4726-4733. doi: 10.1158/1078-0432.CCR-18-0208. Epub 2018 Jul 3.

PMID:
30084833
2.

Parenclitic networks for predicting ovarian cancer.

Whitwell HJ, Blyuss O, Menon U, Timms JF, Zaikin A.

Oncotarget. 2018 Apr 27;9(32):22717-22726. doi: 10.18632/oncotarget.25216. eCollection 2018 Apr 27.

3.

Identification of a serum biomarker panel for the differential diagnosis of cholangiocarcinoma and primary sclerosing cholangitis.

Cuenco J, Wehnert N, Blyuss O, Kazarian A, Whitwell HJ, Menon U, Dawnay A, Manns MP, Pereira SP, Timms JF.

Oncotarget. 2018 Apr 3;9(25):17430-17442. doi: 10.18632/oncotarget.24732. eCollection 2018 Apr 3.

4.

Evidence against Stable Protein S-Nitrosylation as a Widespread Mechanism of Post-translational Regulation.

Wolhuter K, Whitwell HJ, Switzer CH, Burgoyne JR, Timms JF, Eaton P.

Mol Cell. 2018 Feb 1;69(3):438-450.e5. doi: 10.1016/j.molcel.2017.12.019. Epub 2018 Jan 18.

5.

Evidence of Altered Glycosylation of Serum Proteins Prior to Pancreatic Cancer Diagnosis.

Krishnan S, Whitwell HJ, Cuenco J, Gentry-Maharaj A, Menon U, Pereira SP, Gaspari M, Timms JF.

Int J Mol Sci. 2017 Dec 9;18(12). pii: E2670. doi: 10.3390/ijms18122670.

6.

Effects of ErbB2 Overexpression on the Proteome and ErbB Ligand-specific Phosphosignaling in Mammary Luminal Epithelial Cells.

Worthington J, Spain G, Timms JF.

Mol Cell Proteomics. 2017 Apr;16(4):608-621. doi: 10.1074/mcp.M116.061267. Epub 2017 Feb 7.

7.

EVERREST prospective study: a 6-year prospective study to define the clinical and biological characteristics of pregnancies affected by severe early onset fetal growth restriction.

Spencer R, Ambler G, Brodszki J, Diemert A, Figueras F, Gratacós E, Hansson SR, Hecher K, Huertas-Ceballos A, Marlow N, Marsál K, Morsing E, Peebles D, Rossi C, Sebire NJ, Timms JF, David AL; EVERREST Consortium.

BMC Pregnancy Childbirth. 2017 Jan 23;17(1):43. doi: 10.1186/s12884-017-1226-7.

8.

Proteomic Analysis of Kveim Reagent Identifies Targets of Cellular Immunity in Sarcoidosis.

Eberhardt C, Thillai M, Parker R, Siddiqui N, Potiphar L, Goldin R, Timms JF, Wells AU, Kon OM, Wickremasinghe M, Mitchell D, Weeks ME, Lalvani A.

PLoS One. 2017 Jan 23;12(1):e0170285. doi: 10.1371/journal.pone.0170285. eCollection 2017.

9.

Testing breast cancer serum biomarkers for early detection and prognosis in pre-diagnosis samples.

Kazarian A, Blyuss O, Metodieva G, Gentry-Maharaj A, Ryan A, Kiseleva EM, Prytomanova OM, Jacobs IJ, Widschwendter M, Menon U, Timms JF.

Br J Cancer. 2017 Feb 14;116(4):501-508. doi: 10.1038/bjc.2016.433. Epub 2017 Jan 12.

10.

Disulfide-activated protein kinase G Iα regulates cardiac diastolic relaxation and fine-tunes the Frank-Starling response.

Scotcher J, Prysyazhna O, Boguslavskyi A, Kistamas K, Hadgraft N, Martin ED, Worthington J, Rudyk O, Rodriguez Cutillas P, Cuello F, Shattock MJ, Marber MS, Conte MR, Greenstein A, Greensmith DJ, Venetucci L, Timms JF, Eaton P.

Nat Commun. 2016 Oct 26;7:13187. doi: 10.1038/ncomms13187.

11.

Advances in mass spectrometry-based cancer research and analysis: from cancer proteomics to clinical diagnostics.

Timms JF, Hale OJ, Cramer R.

Expert Rev Proteomics. 2016 Jun;13(6):593-607. doi: 10.1080/14789450.2016.1182431. Epub 2016 May 6. Review.

PMID:
27109265
12.

Surfactant Protein-D Is Essential for Immunity to Helminth Infection.

Thawer S, Auret J, Schnoeller C, Chetty A, Smith K, Darby M, Roberts L, Mackay RM, Whitwell HJ, Timms JF, Madsen J, Selkirk ME, Brombacher F, Clark HW, Horsnell WG.

PLoS Pathog. 2016 Feb 22;12(2):e1005461. doi: 10.1371/journal.ppat.1005461. eCollection 2016 Feb.

13.

Serial Patterns of Ovarian Cancer Biomarkers in a Prediagnosis Longitudinal Dataset.

Blyuss O, Gentry-Maharaj A, Fourkala EO, Ryan A, Zaikin A, Menon U, Jacobs I, Timms JF.

Biomed Res Int. 2015;2015:681416. doi: 10.1155/2015/681416. Epub 2015 Dec 24.

14.

Decreased Serum Thrombospondin-1 Levels in Pancreatic Cancer Patients Up to 24 Months Prior to Clinical Diagnosis: Association with Diabetes Mellitus.

Jenkinson C, Elliott VL, Evans A, Oldfield L, Jenkins RE, O'Brien DP, Apostolidou S, Gentry-Maharaj A, Fourkala EO, Jacobs IJ, Menon U, Cox T, Campbell F, Pereira SP, Tuveson DA, Park BK, Greenhalf W, Sutton R, Timms JF, Neoptolemos JP, Costello E.

Clin Cancer Res. 2016 Apr 1;22(7):1734-1743. doi: 10.1158/1078-0432.CCR-15-0879. Epub 2015 Nov 16.

15.

The phenotype of a knockout mouse identifies flavin-containing monooxygenase 5 (FMO5) as a regulator of metabolic ageing.

Gonzalez Malagon SG, Melidoni AN, Hernandez D, Omar BA, Houseman L, Veeravalli S, Scott F, Varshavi D, Everett J, Tsuchiya Y, Timms JF, Phillips IR, Shephard EA.

Biochem Pharmacol. 2015 Aug 1;96(3):267-77. doi: 10.1016/j.bcp.2015.05.013. Epub 2015 Jun 4.

16.

Evaluation of serum CEA, CYFRA21-1 and CA125 for the early detection of colorectal cancer using longitudinal preclinical samples.

Thomas DS, Fourkala EO, Apostolidou S, Gunu R, Ryan A, Jacobs I, Menon U, Alderton W, Gentry-Maharaj A, Timms JF.

Br J Cancer. 2015 Jul 14;113(2):268-74. doi: 10.1038/bjc.2015.202. Epub 2015 Jun 2.

17.

Evaluation in pre-diagnosis samples discounts ICAM-1 and TIMP-1 as biomarkers for earlier diagnosis of pancreatic cancer.

Jenkinson C, Elliott V, Menon U, Apostolidou S, Fourkala OE, Gentry-Maharaj A, Pereira SP, Jacobs I, Cox TF, Greenhalf W, Timms JF, Sutton R, Neoptolemos JP, Costello E.

J Proteomics. 2015 Jan 15;113:400-2.

PMID:
25316052
18.

Discovery of serum biomarkers of ovarian cancer using complementary proteomic profiling strategies.

Timms JF, Arslan-Low E, Kabir M, Worthington J, Camuzeaux S, Sinclair J, Szaub J, Afrough B, Podust VN, Fourkala EO, Cubizolles M, Kronenberg F, Fung ET, Gentry-Maharaj A, Menon U, Jacobs I.

Proteomics Clin Appl. 2014 Dec;8(11-12):982-93. doi: 10.1002/prca.201400063. Epub 2014 Nov 10.

19.

Identification of novel candidate biomarkers of epithelial ovarian cancer by profiling the secretomes of three-dimensional genetic models of ovarian carcinogenesis.

Lawrenson K, Mhawech-Fauceglia P, Worthington J, Spindler TJ, O'Brien D, Lee JM, Spain G, Sharifian M, Wang G, Darcy KM, Pejovic T, Sowter H, Timms JF, Gayther SA.

Int J Cancer. 2015 Oct 15;137(8):1806-17. doi: 10.1002/ijc.29197. Epub 2015 Jul 2.

20.

Serum CA19-9 is significantly upregulated up to 2 years before diagnosis with pancreatic cancer: implications for early disease detection.

O'Brien DP, Sandanayake NS, Jenkinson C, Gentry-Maharaj A, Apostolidou S, Fourkala EO, Camuzeaux S, Blyuss O, Gunu R, Dawnay A, Zaikin A, Smith RC, Jacobs IJ, Menon U, Costello E, Pereira SP, Timms JF.

Clin Cancer Res. 2015 Feb 1;21(3):622-31. doi: 10.1158/1078-0432.CCR-14-0365. Epub 2014 Jun 17.

21.

Employing TMT quantification in a shotgun-MS platform.

O'Brien DP, Timms JF.

Methods Mol Biol. 2014;1156:187-99. doi: 10.1007/978-1-4939-0685-7_12.

PMID:
24791989
22.

Identification of potential serum peptide biomarkers of biliary tract cancer using MALDI MS profiling.

Sandanayake NS, Camuzeaux S, Sinclair J, Blyuss O, Andreola F, Chapman MH, Webster GJ, Smith RC, Timms JF, Pereira SP.

BMC Clin Pathol. 2014 Feb 4;14(1):7. doi: 10.1186/1472-6890-14-7.

23.

HNRNPA1 interacts with a 5'-flanking distal element of interleukin-6 and upregulates its basal transcription.

Zheng D, Worthington J, Timms JF, Woo P.

Genes Immun. 2013 Dec;14(8):479-86. doi: 10.1038/gene.2013.41. Epub 2013 Aug 29.

24.

Novel diagnostic and prognostic biomarkers in biliary tract cancer.

Skipworth JR, Timms JF, Pereira SP.

Expert Opin Med Diagn. 2013 Sep;7(5):487-99. doi: 10.1517/17530059.2013.826646. Review.

PMID:
23971898
25.

Proteomic profiling of ovarian cancer models using TMT-LC-MS/MS.

Sinclair J, Timms JF.

Methods Mol Biol. 2013;1049:271-84. doi: 10.1007/978-1-62703-547-7_20.

PMID:
23913223
26.

A targeted glycoproteomic approach identifies cadherin-5 as a novel biomarker of metastatic breast cancer.

Fry SA, Sinclair J, Timms JF, Leathem AJ, Dwek MV.

Cancer Lett. 2013 Jan 28;328(2):335-44. doi: 10.1016/j.canlet.2012.10.011. Epub 2012 Oct 16.

PMID:
23079531
27.

Functional proteomic analysis of long-term growth factor stimulation and receptor tyrosine kinase coactivation in Swiss 3T3 fibroblasts.

Nagano K, Akpan A, Warnasuriya G, Corless S, Totty N, Yang A, Stein R, Zvelebil M, Stensballe A, Burlingame A, Waterfield M, Cramer R, Timms JF, Naaby-Hansen S.

Mol Cell Proteomics. 2012 Dec;11(12):1690-708. doi: 10.1074/mcp.M112.019778. Epub 2012 Sep 6.

28.

Hemopexin is up-regulated in plasma from type 1 diabetes mellitus patients: Role of glucose-induced ROS.

Chen CC, Lu YC, Chen YW, Lee WL, Lu CH, Chen YH, Lee YC, Lin ST, Timms JF, Lee YR, Chou HC, Chan HL.

J Proteomics. 2012 Jun 27;75(12):3760-77. doi: 10.1016/j.jprot.2012.04.047. Epub 2012 May 8.

PMID:
22579751
29.

Proteomic and redox-proteomic analysis of berberine-induced cytotoxicity in breast cancer cells.

Chou HC, Lu YC, Cheng CS, Chen YW, Lyu PC, Lin CW, Timms JF, Chan HL.

J Proteomics. 2012 Jun 18;75(11):3158-76. doi: 10.1016/j.jprot.2012.03.010. Epub 2012 Mar 21.

PMID:
22522123
30.

Proteomic analysis of redox-dependent changes using cysteine-labeling 2D DIGE.

Chan HL, Sinclair J, Timms JF.

Methods Mol Biol. 2012;854:113-28. doi: 10.1007/978-1-61779-573-2_8.

PMID:
22311756
31.

Early detection of ovarian cancer in samples pre-diagnosis using CA125 and MALDI-MS peaks.

Timms JF, Menon U, Devetyarov D, Tiss A, Camuzeaux S, McCurrie K, Nouretdinov I, Burford B, Smith C, Gentry-Maharaj A, Hallett R, Ford J, Luo Z, Vovk V, Gammerman A, Cramer R, Jacobs I.

Cancer Genomics Proteomics. 2011 Nov-Dec;8(6):289-305.

PMID:
22086897
32.

A combination of serum leucine-rich α-2-glycoprotein 1, CA19-9 and interleukin-6 differentiate biliary tract cancer from benign biliary strictures.

Sandanayake NS, Sinclair J, Andreola F, Chapman MH, Xue A, Webster GJ, Clarkson A, Gill A, Norton ID, Smith RC, Timms JF, Pereira SP.

Br J Cancer. 2011 Oct 25;105(9):1370-8. doi: 10.1038/bjc.2011.376. Epub 2011 Oct 4.

33.

AGR2 is a novel surface antigen that promotes the dissemination of pancreatic cancer cells through regulation of cathepsins B and D.

Dumartin L, Whiteman HJ, Weeks ME, Hariharan D, Dmitrovic B, Iacobuzio-Donahue CA, Brentnall TA, Bronner MP, Feakins RM, Timms JF, Brennan C, Lemoine NR, Crnogorac-Jurcevic T.

Cancer Res. 2011 Nov 15;71(22):7091-102. doi: 10.1158/0008-5472.CAN-11-1367. Epub 2011 Sep 26.

34.

IMAC/TiO(2) enrich for peptide modifications other than phosphorylation: implications for chromatographic choice and database searching in phosphoproteomics.

Worthington J, Cutillas PR, Timms JF.

Proteomics. 2011 Dec;11(23):4583-7. doi: 10.1002/pmic.201100143. Epub 2011 Oct 24.

PMID:
21932442
35.

Identification of aldo-keto reductase AKR1B10 as a selective target for modification and inhibition by prostaglandin A(1): implications for antitumoral activity.

Díez-Dacal B, Gayarre J, Gharbi S, Timms JF, Coderch C, Gago F, Pérez-Sala D.

Cancer Res. 2011 Jun 15;71(12):4161-71. doi: 10.1158/0008-5472.CAN-10-3816. Epub 2011 Apr 20.

36.

Lectin microarray profiling of metastatic breast cancers.

Fry SA, Afrough B, Lomax-Browne HJ, Timms JF, Velentzis LS, Leathem AJ.

Glycobiology. 2011 Aug;21(8):1060-70. doi: 10.1093/glycob/cwr045. Epub 2011 Apr 19.

PMID:
21507904
37.

Quantitative profiling of serum samples using TMT protein labelling, fractionation and LC-MS/MS.

Sinclair J, Timms JF.

Methods. 2011 Aug;54(4):361-9. doi: 10.1016/j.ymeth.2011.03.004. Epub 2011 Mar 21.

PMID:
21397697
38.

Highly accurate detection of ovarian cancer using CA125 but limited improvement with serum matrix-assisted laser desorption/ionization time-of-flight mass spectrometry profiling.

Tiss A, Timms JF, Smith C, Devetyarov D, Gentry-Maharaj A, Camuzeaux S, Burford B, Nouretdinov I, Ford J, Luo Z, Jacobs I, Menon U, Gammerman A, Cramer R.

Int J Gynecol Cancer. 2010 Dec;20(9):1518-24.

PMID:
21370595
39.

Profiling signatures of ovarian cancer tumour suppression using 2D-DIGE and 2D-LC-MS/MS with tandem mass tagging.

Sinclair J, Metodieva G, Dafou D, Gayther SA, Timms JF.

J Proteomics. 2011 Apr 1;74(4):451-65. doi: 10.1016/j.jprot.2010.12.009. Epub 2011 Jan 13.

PMID:
21237297
40.

Transcriptional profiling of ErbB signalling in mammary luminal epithelial cells--interplay of ErbB and IGF1 signalling through IGFBP3 regulation.

Worthington J, Bertani M, Chan HL, Gerrits B, Timms JF.

BMC Cancer. 2010 Sep 14;10:490. doi: 10.1186/1471-2407-10-490.

41.

Overview of quantitative LC-MS techniques for proteomics and activitomics.

Timms JF, Cutillas PR.

Methods Mol Biol. 2010;658:19-45. doi: 10.1007/978-1-60761-780-8_2. Review.

PMID:
20839096
42.

Approaches and applications of quantitative LC-MS for proteomics and activitomics.

Cutillas PR, Timms JF.

Methods Mol Biol. 2010;658:3-17. doi: 10.1007/978-1-60761-780-8_1. Review.

PMID:
20839095
43.

A well-characterised peak identification list of MALDI MS profile peaks for human blood serum.

Tiss A, Smith C, Menon U, Jacobs I, Timms JF, Cramer R.

Proteomics. 2010 Sep;10(18):3388-92. doi: 10.1002/pmic.201000100.

PMID:
20707003
44.

Molecular characterisation of post-bio-electrosprayed human brain astrocytoma cells.

Eddaoudi A, Townsend-Nicholson A, Timms JF, Schorge S, Jayasinghe SN.

Analyst. 2010 Oct;135(10):2600-12. doi: 10.1039/c0an00213e. Epub 2010 Aug 6.

PMID:
20694206
45.

Proteomics study of oxidative stress and Src kinase inhibition in H9C2 cardiomyocytes: a cell model of heart ischemia-reperfusion injury and treatment.

Chou HC, Chen YW, Lee TR, Wu FS, Chan HT, Lyu PC, Timms JF, Chan HL.

Free Radic Biol Med. 2010 Jul 1;49(1):96-108. doi: 10.1016/j.freeradbiomed.2010.04.001. Epub 2010 Apr 9.

PMID:
20385227
46.

Peptides generated ex vivo from serum proteins by tumor-specific exopeptidases are not useful biomarkers in ovarian cancer.

Timms JF, Cramer R, Camuzeaux S, Tiss A, Smith C, Burford B, Nouretdinov I, Devetyarov D, Gentry-Maharaj A, Ford J, Luo Z, Gammerman A, Menon U, Jacobs I.

Clin Chem. 2010 Feb;56(2):262-71. doi: 10.1373/clinchem.2009.133363. Epub 2010 Jan 21.

47.

Major role of epidermal growth factor receptor and Src kinases in promoting oxidative stress-dependent loss of adhesion and apoptosis in epithelial cells.

Chan HL, Chou HC, Duran M, Gruenewald J, Waterfield MD, Ridley A, Timms JF.

J Biol Chem. 2010 Feb 12;285(7):4307-18. doi: 10.1074/jbc.M109.047027. Epub 2009 Dec 7.

48.

A biotinylated analog of the anti-proliferative prostaglandin A1 allows assessment of PPAR-independent effects and identification of novel cellular targets for covalent modification.

Garzón B, Gayarre J, Gharbi S, Díez-Dacal B, Sánchez-Gómez FJ, Timms JF, Pérez-Sala D.

Chem Biol Interact. 2010 Jan 5;183(1):212-21. doi: 10.1016/j.cbi.2009.09.019.

PMID:
19800325
49.

Identification of oxidative stress-induced tyrosine phosphorylated proteins by immunoprecipitation and mass spectrometry.

Duran MC, Chan HL, Timms JF.

Methods Mol Biol. 2009;527:33-45, ix. doi: 10.1007/978-1-60327-834-8_3.

PMID:
19241003
50.

Three-dimensional in vitro cell biology models of ovarian and endometrial cancer.

Grun B, Benjamin E, Sinclair J, Timms JF, Jacobs IJ, Gayther SA, Dafou D.

Cell Prolif. 2009 Apr;42(2):219-28. doi: 10.1111/j.1365-2184.2008.00579.x. Epub 2009 Feb 16.

PMID:
19222485

Supplemental Content

Loading ...
Support Center